Please note that the ANZCTR website will be unavailable from 12am until 6am (AEST) on Sunday 22nd September 2019. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
Cardiovascular function with switching from Kivexa to Truvada (or from Abacavir to Tenofovir).
Scientific title
Cardiovascular function with switching from Kivexa to Truvada (or from Abacavir to Tenofovir) in people with Human Immunodeficiency Virus (HIV).
Secondary ID [1] 282896 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Human Immunodeficiency Virus (HIV) 3982 0
Cardiovascular function 3983 0
Condition category
Condition code
Infection 4180 4180 0 0
Acquired immune deficiency syndrome (AIDS / HIV)

Study type
Description of intervention(s) / exposure
using applanation tonometry to evaluate cardiovascular function in adults with HIV infection switching from ABC-3TC (Kivexa) to TDF-FTC (Truvada) or from ABC (abacavir) to TDF (tenofovir).
Kivexa is a combination HIV pill of Abacavir and lamivudine and Abacavir alone is one of the two drugs in Kivexa. Truvada, another combination pill that contains the drugs tenofovir and emtricitabine and Tenofovir alone is one of the two drugs in Truvada. Truvada and Tenofovir are the two drugs to be used in this study. This is a 24 week study
Truvada dose is 1 x 300mg/200mg tablet, once daily, oral for 24 weeks.
Tenofovir dose is 1 x 300mg tablet, once daily oral for 24 weeks.
Intervention code [1] 3703 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 5070 0
To evaluate cardiovascular function measured by radial artery applanation tonometry in HIV-infected adults switching from ABC-3TC to TDF-FTC (or from ABC to TDF).
Timepoint [1] 5070 0
Baseline and at twenty four weeks
Secondary outcome [1] 8522 0
To relate these functional arterial changes to HIV-related, metabolic and pro-inflammatory parameters. This will be done by looking at Tonometry reports done at various timepoints throughout the study as well as pathology blood results
Timepoint [1] 8522 0
twenty four weeks after the start of the study.
The outcome will be assessed also at weeks 4 and 12.

Key inclusion criteria
provision of written, informed consent.
HIV-infected adults at least 18 years of age.
receiving stable antiretroviral therapy including ABC or ABC-3TC for at least six months.
HIV Ribonucleic Acid (RNA) < 50 copies/ml for at least the previous 3 months.
Framingham risk score = 10%, OR diabetes, OR prior ischaemic cardiovascular disease.
Minimum age
18 Years
Maximum age
200 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
clinically significant renal or hepatic disease.
initiation of anti hypertensive therapy in the previous 30 days.
initiation of therapy for dyslipidaemia in the previous 6 weeks.
using corticosteroids, anti-inflammatory drugs or immunomodulating drugs.
contra-indications to TDF or TDF-FTC therapy (e.g. grade 3 renal dysfunction).

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 11212 0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Recruitment postcode(s) [1] 23086 0
2010 - Darlinghurst

Funding & Sponsors
Funding source category [1] 4171 0
Name [1] 4171 0
St Vincents Hospital
Address [1] 4171 0
390 Victoria St, Darlinghurst, NSW 2010
Country [1] 4171 0
Primary sponsor type
St Vincents Hospital
390 Victoria St, Darlinghurst, NSW 2010
Secondary sponsor category [1] 3746 0
Name [1] 3746 0
Address [1] 3746 0
Country [1] 3746 0

Ethics approval
Ethics application status

Brief summary
The purpose is to perform tonometry in HIV-infected adults before and after switching their HIV treatment from Kivexa to Truvada (or from Abacavir to Tenofovir).
Hypothesis: that markers of cardiovascular function (as measured by applanation tonometry) will improve in patients switching from ABC-3TC to TDF-FTC.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 29133 0
Prof Andrew Carr
Address 29133 0
St Vincents Hospital
Xavier, Level 4, 390 Victortoria St
Darlinghurst, NSW, 2010
Country 29133 0
Phone 29133 0
+61 2 83823359
Fax 29133 0
Email 29133 0
Contact person for public queries
Name 12290 0
Ms Registered Nurse (RN) Kate Sinn
Address 12290 0
St Vincents Hospital
Level 4 Xavier Bldg
390 Victoria St, Darlinghurst, NSW 2010
Country 12290 0
Phone 12290 0
+61 2 8382 3060
Fax 12290 0
Email 12290 0
Contact person for scientific queries
Name 3218 0
Prof Professor Andrew Carr
Address 3218 0
St Vincents Hospital
Level 4 Xavier Bldg
390 Victoria St, Darlinghurst, NSW 2010
Country 3218 0
Phone 3218 0
+61 2 8382 3359
Fax 3218 0
Email 3218 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary